胃肠胰神经内分泌肿瘤靶向肽受体放射性核素正电子发射断层成像与治疗的现状与未来。
Current status and future of targeted peptide receptor radionuclide positron emission tomography imaging and therapy of gastroenteropancreatic-neuroendocrine tumors.
机构信息
Radiology-Nuclear Medicine, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO 80045, United States.
Department of Radiology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO 80045, United States.
出版信息
World J Gastroenterol. 2022 May 7;28(17):1768-1780. doi: 10.3748/wjg.v28.i17.1768.
Abstract
Theranostics is the highly targeted molecular imaging and therapy of tumors. Targeted peptide receptor radionuclide therapy has taken the lead in demonstrating the safety and effectiveness of this molecular approach to treating cancers. Metastatic, well-differentiated gastroenteropancreatic neuroendocrine tumors may be most effectively imaged and treated with DOTATATE ligands. We review the current practice, safety, advantages, and limitations of DOTATATE based theranostics. Finally, we briefly describe the exciting new areas of development and future directions of gastroenteropancreatic neuroendocrine tumor theranostics.
摘要
治疗学是一种针对肿瘤的高靶向性分子成像和治疗方法。靶向肽受体放射性核素治疗率先证明了这种治疗癌症的分子方法的安全性和有效性。转移性、高分化的胃肠胰神经内分泌肿瘤可以通过 DOTATATE 配体得到最有效的成像和治疗。我们回顾了基于 DOTATATE 的治疗学的当前实践、安全性、优势和局限性。最后，我们简要描述了胃肠胰神经内分泌肿瘤治疗学令人兴奋的新发展领域和未来方向。
相似文献
1
Current status and future of targeted peptide receptor radionuclide positron emission tomography imaging and therapy of gastroenteropancreatic-neuroendocrine tumors.胃肠胰神经内分泌肿瘤靶向肽受体放射性核素正电子发射断层成像与治疗的现状与未来。
World J Gastroenterol. 2022 May 7;28(17):1768-1780. doi: 10.3748/wjg.v28.i17.1768.
2
Impact of initial imaging with gallium-68 dotatate PET/CT on diagnosis and management of patients with neuroendocrine tumors.镓-68 生长抑素 PET/CT 初始显像对神经内分泌肿瘤患者诊断和治疗的影响。
J Surg Oncol. 2020 Mar;121(3):480-485. doi: 10.1002/jso.25812. Epub 2019 Dec 18.
3
Correlation and Comparison of Somatostatin Receptor Type 2 Immunohistochemical Scoring Systems with 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography Imaging in Gastroenteropancreatic Neuroendocrine Neoplasms.胃胰神经内分泌肿瘤中生长抑素受体 2 免疫组织化学评分系统与 68Ga-DOTATATE 正电子发射断层扫描/计算机断层成像的相关性和比较。
Neuroendocrinology. 2022;112(4):358-369. doi: 10.1159/000517530. Epub 2021 Jun 2.
4
Lobular breast cancer bone metastases detected with Ga-DOTATATE PET/CT performed for intestinal neuroendocrine tumor.因肠道神经内分泌肿瘤行镓- DOTATATE PET/CT检查时发现的小叶型乳腺癌骨转移。
Rev Esp Med Nucl Imagen Mol (Engl Ed). 2022;41 Suppl 1:S44-S45. doi: 10.1016/j.remnie.2021.09.002. Epub 2021 Sep 27.
5
Theranostics in Neuroendocrine Tumors.神经内分泌肿瘤的治疗学诊断。
Cancer J. 2024;30(3):185-193. doi: 10.1097/PPO.0000000000000723.
6
Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE.使用¹⁷⁷Lu-DOTATATE的肽受体放射性核素治疗对胰腺神经内分泌肿瘤的剂量反应。
J Nucl Med. 2015 Feb;56(2):177-82. doi: 10.2967/jnumed.114.148437. Epub 2015 Jan 15.
7
Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.基于¹⁷⁷Lu-DOTATATE的肽受体放射性核素治疗在转移性胃肠胰神经内分泌肿瘤中的应用：一项与原发肿瘤部位、肿瘤增殖指数及双示踪剂成像特征相关的多参数反应评估
Nucl Med Commun. 2016 Oct;37(10):1030-7. doi: 10.1097/MNM.0000000000000547.
8
Differential uptake of (68)Ga-DOTATOC and (68)Ga-DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumors.(68)Ga-DOTATOC与(68)Ga-DOTATATE在胃肠胰神经内分泌肿瘤PET/CT中的摄取差异
Recent Results Cancer Res. 2013;194:353-71. doi: 10.1007/978-3-642-27994-2_18.
9
Neuroendocrine tumor theranostics.神经内分泌肿瘤的治疗与诊断。
Cancer Sci. 2022 Jun;113(6):1930-1938. doi: 10.1111/cas.15327. Epub 2022 Apr 11.
10
Management of a Patient With Metastatic Gastrointestinal Neuroendocrine Tumor and Meningioma Submitted to Peptide Receptor Radionuclide Therapy With 177 Lu-DOTATATE.一名患有转移性胃肠道神经内分泌肿瘤和脑膜瘤的患者接受¹⁷⁷Lu-DOTATATE肽受体放射性核素治疗的管理
Clin Nucl Med. 2022 Nov 1;47(11):e692-e695. doi: 10.1097/RLU.0000000000004307. Epub 2022 Jun 11.
引用本文的文献
1
Molecular imaging using (nano)probes: cutting-edge developments and clinical challenges in diagnostics.使用（纳米）探针的分子成像：诊断学中的前沿进展与临床挑战
RSC Adv. 2025 Jul 14;15(30):24696-24725. doi: 10.1039/d5ra03927d. eCollection 2025 Jul 10.
2
Feasibility of a deep-inspiration breath-hold [F]AlF-NOTA-LM3 PET/CT imaging on upper-abdominal lesions in NET patients: in comparison with respiratory-gated PET/CT.深度吸气屏气[F]AlF-NOTA-LM3 PET/CT成像用于神经内分泌肿瘤（NET）患者上腹部病变的可行性：与呼吸门控PET/CT的比较
EJNMMI Phys. 2024 Aug 29;11(1):75. doi: 10.1186/s40658-024-00677-5.
3
Pancreatic neuroendocrine tumor detected by technetium-99m methoxy-2-isobutylisonitrile single photon emission computed tomography/computed tomography: A case report.通过锝-99m甲氧基-2-异丁基异腈单光子发射计算机断层扫描/计算机断层扫描检测到的胰腺神经内分泌肿瘤：一例报告。
World J Clin Cases. 2023 Apr 26;11(12):2825-2831. doi: 10.12998/wjcc.v11.i12.2825.
本文引用的文献
1
A prospective randomized, double-blind study to evaluate the diagnostic efficacy of Ga-NODAGA-LM3 and Ga-DOTA-LM3 in patients with well-differentiated neuroendocrine tumors: compared with Ga-DOTATATE.一项前瞻性随机、双盲研究，旨在评估 Ga-NODAGA-LM3 和 Ga-DOTA-LM3 在分化良好的神经内分泌肿瘤患者中的诊断效能：与 Ga-DOTATATE 相比。
Eur J Nucl Med Mol Imaging. 2022 Apr;49(5):1613-1622. doi: 10.1007/s00259-021-05512-y. Epub 2021 Dec 7.
2
Small target repeatability of Ga and F: effects of target concentration and imaging time on SUV measurements in clinically relevant phantoms.镓和氟的小目标重复性：目标浓度和成像时间对临床相关体模中标准化摄取值测量的影响
Am J Nucl Med Mol Imaging. 2021 Aug 15;11(4):280-289. eCollection 2021.
3
Dosing Ac-DOTATOC in patients with somatostatin-receptor-positive solid tumors: 5-year follow-up of hematological and renal toxicity.阿曲库铵在生长抑素受体阳性实体瘤患者中的给药剂量：血液学和肾脏毒性的 5 年随访。
Eur J Nucl Med Mol Imaging. 2021 Dec;49(1):54-63. doi: 10.1007/s00259-021-05474-1. Epub 2021 Aug 26.
4
Prognostic Value of 18F-FDG PET in Neuroendocrine Neoplasm: A Systematic Review and Meta-analysis.18F-FDG PET 在神经内分泌肿瘤中的预后价值：系统评价和荟萃分析。
Clin Nucl Med. 2021 Sep 1;46(9):723-731. doi: 10.1097/RLU.0000000000003682.
5
Physical characteristics of Ga DOTATATE PET/CT affecting small lesion detectability.镓 DOTATATE PET/CT 的物理特性对小病灶可检测性的影响。
Am J Nucl Med Mol Imaging. 2021 Feb 15;11(1):27-39. eCollection 2021.
6
First-in-Humans Study of the SSTR Antagonist Lu-DOTA-LM3 for Peptide Receptor Radionuclide Therapy in Patients with Metastatic Neuroendocrine Neoplasms: Dosimetry, Safety, and Efficacy.首个人体研究 Lu-DOTA-LM3 作为生长抑素受体放射性核素治疗转移性神经内分泌肿瘤患者的 SSTR 拮抗剂：剂量学、安全性和疗效。
J Nucl Med. 2021 Nov;62(11):1571-1581. doi: 10.2967/jnumed.120.258889. Epub 2021 Mar 5.
7
Semiautomatic Tumor Delineation for Evaluation of Cu-DOTATATE PET/CT in Patients with Neuroendocrine Neoplasms: Prognostication Based on Lowest Lesion Uptake and Total Tumor Volume.半自动化肿瘤勾画在评估神经内分泌肿瘤患者 ^177Lu-DOTATATE PET/CT 中的应用：基于最低病变摄取和肿瘤总体积的预后价值。
J Nucl Med. 2021 Nov;62(11):1564-1570. doi: 10.2967/jnumed.120.258392. Epub 2021 Feb 26.
8
A Prospective, Randomized, Double-Blind Study to Evaluate the Safety, Biodistribution, and Dosimetry of Ga-NODAGA-LM3 and Ga-DOTA-LM3 in Patients with Well-Differentiated Neuroendocrine Tumors.一项前瞻性、随机、双盲研究，旨在评估 Ga-NODAGA-LM3 和 Ga-DOTA-LM3 在分化良好的神经内分泌肿瘤患者中的安全性、生物分布和剂量学。
J Nucl Med. 2021 Oct;62(10):1398-1405. doi: 10.2967/jnumed.120.253096. Epub 2021 Feb 12.
9
Peptide receptor radiotherapy re-treatment in patients with progressive neuroendocrine tumors: A systematic review and meta-analysis.肽受体放射性核素治疗进展性神经内分泌肿瘤患者的再治疗：系统评价和荟萃分析。
Cancer Treat Rev. 2021 Feb;93:102141. doi: 10.1016/j.ctrv.2020.102141. Epub 2020 Dec 22.
10
Targeted Alpha Therapy: Progress in Radionuclide Production, Radiochemistry, and Applications.靶向α治疗：放射性核素生产、放射化学及应用的进展
Pharmaceutics. 2020 Dec 31;13(1):49. doi: 10.3390/pharmaceutics13010049.
Zotero 插件